Coherus BioSciences (CHRS) Tops Q2 EPS by 11c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.39 -2.11%
EPS Growth %: +39.4%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: +39.4%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $65 million versus the consensus estimate of $56.41 million.
GUIDANCE:
Coherus BioSciences sees FY2024 revenue of $250-265 million, versus the consensus of $259.3 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
- John Wiley & Sons, Inc. (WLY) Misses Q1 EPS by 2c ; Offers Guidance
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
